Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC69592 structure
    GC69592NRP1 antagonist 1
    CAS: 2569598-01-0
    纯度: >99.00%

    NRP1 antagonist 1 (compound 12a) 是一种有效的 NRP1 拮抗剂,IC50 为 19.1 μM。NRP1 antagonist 1 具有用于癌症研究的潜力。

  • GC69595 structure
    GC69595NSC61610
    CAS: 500538-94-3
    纯度: >99.00%

    NSC61610 破坏 hIL-18 与 ectromelia 病毒 IL-18BP 的结合。NSC61610 抑制 hIL-18:ectvIL-18BP 复合物形成,IC50 约为 6 uM。

  • GC69609 structure
    GC69609ODN 2007
    CAS: 455348-63-7
    纯度: >93.00%

    ODN 2007 为 B 类 CpG ODN (寡脱氧核苷酸), 是一种 Toll 样受体 (TLR) 配体。ODN 2007 可作为免疫调节剂、疫苗佐剂,增强哺乳动物、鱼类和人类的免疫反应。ODN 2007 序列:5'-TCGTCGTTGTCGTTTTGTCGTT-3'。

  • GC69610 structure
    GC69610ODN 20844
    CAS: 1964506-29-3
    纯度: >96.00%

    ODN 20844,鸟嘌呤修饰的抑制性寡核苷酸 (INH-ODN),是一种 TLR7 和 TLR9 (Toll-like receptor) 的抑制剂,其亲本为 INH-ODN 2088。ODN 20844 可以破坏 TLR7 和 TLR9 介导的免疫细胞免疫反应。ODN 20844 序列:5'-TCCTGGCGc7GGGAAGT-3'。

  • GC69611 structure
    GC69611ODN 2336
    CAS: 332956-64-6
    纯度: >90.00%

    ODN 2336 是 A 类 CpG ODN(寡脱氧核苷酸),是一种有效的 TLR9 激动剂。ODN 2336 诱导 IFN-α 的产生。ODN 2336 上调 IP-10 mRNA 和 IL-18 mRNA的表达。ODN 2336 可用作疫苗的佐剂。

  • GC69612 structure
    GC69612ODN 24987
    CAS: 1682661-48-8
    纯度: >92.00%

    ODN 24987 是一种鸟嘌呤修饰的抑制性寡核苷酸 (ODN),靶向 TLR9。ODN 24987 可抑制 IL-6 和 IFN-α 的释放。ODN 24987 可用于研究免疫紊乱。ODN 24987 序列:5'-C-C-T-G-G-C-c7G-G-G-G-3'。

  • GC69613 structure
    GC69613ODN 6016
    CAS: 1271731-64-6
    纯度: >94.00%

    ODN 6016 是一种 CpG-A 寡核苷酸。ODN 6016 可诱导 IFN-α 产生,可用于研究免疫紊乱,包括 HIV-1 引起的免疫缺陷。ODN 6016 序列:T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G。

  • GC69614 structure
    GC69614ODN D-SL01
    CAS: 1198621-84-9
    纯度: >99.00%

    ODN D-SL01 为 B 类 CpG ODN (寡脱氧核苷酸),是一种 TLR9 激动剂。ODN D-SL01 具有强烈的免疫刺激活性,适用于多种脊椎动物物种,具有抗癌活性。ODN D-SL01 序列:5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3'。

  • GC69615 structure
    GC69615ODN D-SL03
    CAS: 1198621-85-0
    纯度: >99.00%

    ODN D-SL03 是一种 C 类 CpG 寡核苷酸,可诱导刺激 PBMCs 产生高水平 IFN-α。ODN D-SL03 可激活人 B 细胞、NK 细胞和单个核细胞,上调人 PBMCs 亚群表面 CD80、CD86 和 HLA-DR 的表达。ODN D-SL03 也能抑制肿瘤的生长。ODN D-SL03 序列:5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'。

  • GC69621 structure
    GC69621Olokizumab
    CAS: 1007223-17-7
    纯度: >95.00%

    Olokizumab (CDP 6038) 是一种靶向白细胞介素-6 (IL-6) 的人源化单克隆抗体。Olokizumab 可用于类风湿关节炎 (RA) 的研究。

  • GC69631 structure
    GC69631Ordesekimab
    CAS: 879293-15-9
    纯度: >95.00%

    Ordesekimab (AMG 714; PRV-015) 是一种人 IgG1κ 抗 IL-15 (Interleukin Related) 单克隆抗体。Ordesekimab 与 IL-15 的结合抑制 IL-15 与 IL-2Rβ 和 IL-15 受体复合物的共同 γ 链的相互作用,但不与 IL-15Rα 链相互作用。Ordesekimab 具有研究无反应性乳糜泻 (NRCD) 的潜力。

  • GC69641 structure
    GC69641Oxelumab
    CAS: 1186098-83-8
    纯度: >95.00%

    Oxelumab (R 4930) 是一种靶向 OX40 配体 (OX40L) 的人单克隆抗体。Oxelumab 可用于哮喘的研究。

  • GC69684 structure
    GC69684Pelecopan
    CAS: 2378380-49-3
    纯度: >97.00%

    Pelecopan (BCX9930) 是一种有效的、选择性的补体因子 D 抑制剂,具有口服活性。IC50 值为 14.3 nM。Pelecopan 可靶向补体因子 D 以预防 PNH 中的血管内和血管外溶血,也可用于其他替代途径介导的疾病。

  • GC69705 structure
    GC69705Physalin A
    CAS: 23027-91-0

    Physalin A 是一种从 Physalis alkekengi var franchetii 中分离出来的 withanolide。 Physalin A 诱导细胞凋亡 (apoptosis) 与 caspase-3 和 caspase-8 表达上调相关的。Physalin A 诱导自噬,发现可拮抗 HT1080 细胞的凋亡。Physalin A具有研究癌症疾病的潜力。

  • GC69713 structure
    GC69713Pivekimab
    CAS: 2234335-84-1
    纯度: >96.00%

    Pivekimab 是一种靶向 白介素 3 (IL-3) 和 CD123 的人 IgG1 单克隆抗体。Pivekimab 可用于母细胞浆细胞样树突状细胞肿瘤 (BPDCN) 的研究。

  • GC69799 structure
    GC69799(Rac)-ZLc-002
    纯度: >98.00%

    (Rac)-ZLc-002 是 nNOS 与一氧化氮合酶 1 衔接蛋白 (NOS1AP) 相互作用的抑制剂,抑制炎症性痛觉和化疗诱导的神经性疼痛,并与 Paclitaxel 协同降低肿瘤细胞活力。

  • GC69803 structure
    GC69803Ravulizumab
    CAS: 1803171-55-2
    纯度: >95.00%

    Ravulizumab (ALXN1210) 是一种人源化单克隆抗体,它以高亲和力特异性结合人补体蛋白 C5。Ravulizumab 可用于阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征和重症肌无力的研究。

  • GC69806 structure
    GC69806RDR 02308
    CAS: 4155-82-2

    RDR 02308 是 TLR4-MyD88 结合抑制剂,可抑制全长 β-lactamase。

  • GC69818 structure
    GC69818Risankizumab
    CAS: 1612838-76-2
    纯度: >97.00%

    Risankizumab (BI 655066) 是一种人源化 IgG 单克隆抗体,靶向 IL-23 p19 亚基(Kd <10 pM),并能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生(IC50 = 2 pM)。Risankizumab 可用于研究免疫性和炎症性疾病,如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病。

  • GC69823 structure
    GC69823(R)-(-)-Ibuprofen-d3
    CAS: 121702-86-1

    (R)-(-)-Ibuprofen-d3 是 (R)-(-)-Ibuprofen 的氘代物。(R)-(-)-Ibuprofen 是 Ibuprofen 的 R 型异构体,对 COX 无作用,可以抑制 NF-κB 的活化;(R)-(-)-Ibuprofen 具有抗炎作用,可用于缓解疼痛的研究。

  • GC69828 structure
    GC69828Rolinsatamab
    CAS: 2095467-30-2
    纯度: >97.00%

    Rolinsatamab 是一种有效的 IL-4 和 IL-13 双重抑制剂,是一种完全人源化的双特异性单克隆抗体。Rolinsatamab 嵌合抗原受体序列 T 细胞。Rolinsatamab 可用于免疫疾病的研究。

  • GC69831 structure
    GC69831ROS-ERS inducer 1

    ROS-ERS inducer 1 是一种 II 型 ICD (免疫原性细胞死亡) 诱导剂。ROS-ERS inducer 1 是一种源自 4,5-二芳基咪唑的 Pt(II)-N-杂环卡宾 (Pt(II)-NHC) 复合物。ROS-ERS inducer 1 成功诱导内质网应激 (ERS) 伴随活性氧 (ROS) 的产生,并最终导致 HCC 细胞中损伤相关分子模式 (DAMP) 的释放。ROS-ERS inducer 1 显示出比 Cisplatin 高得多的抗癌活性。

  • GC69841 structure
    GC69841Rubropunctatin
    CAS: 514-67-0
    纯度: >98.00%

    Rubropunctatin 是一种从红曲霉发酵米(红霉米)提取物中分离出来的橙色的氮杂酮类色素。 Rubropunctatin 具有抗炎,免疫抑制和抗氧化作用,还具有抗肿瘤活性。

  • GC69889 structure
    GC69889Sifalimumab
    CAS: 1006877-41-3
    纯度: >98.00%

    Sifalimumab (MEDI-545) 是一种 anti-IFNα 单克隆抗体,通过与多种干扰素-α 亚型结合来抑制异常的免疫活动。Sifalimumab 可用于系统性红斑狼疮 (SLE) 的研究。